
Marla Keller
Executive Dean · Montefiore Medical Center/Albert Einstein College of Medicine
Credentials: · ·
History
- 1996–1998
Beth Israel Hospital and fellowship in the combined
Clinical Research Training Program at Mount Sinai School of Medicine
- 1993–1996
Beth Israel Hospital
1989–1993
1985–1989
Research
Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients
Science Translational Medicine · 2020 · 290 citations
Human alpha- and beta-defensins block multiple steps in herpes simplex virus infection
The Journal of Immunology · 2006 · 216 citations
HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes
American Journal of Transplantation · 2008 · 195 citations

53 papers

12 papers

12 papers

10 papers

9 papers
- SM
9 papers

8 papers

8 papers
Grants
- 2023–2030
Einstein-Montefiore Clinical and Translational Science Award Hub
National Center for Advancing Translational Sciences · UM1
Contact PI · $4.4M · Albert Einstein College of Medicine
- 2018–2023
Clinical and Translational Science Award
National Center for Advancing Translational Sciences · UL1
Contact PI · $26.7M · Albert Einstein College of Medicine
- 2013–2018
Drug at the Right Place & Concentration: Optimizing Combination Vaginal Ring PrEP
National Institute of Allergy and Infectious Diseases · U19
Project lead · $4.3M · Albert Einstein College of Medicine
- 2013–2018
Clinical and Translational Science Award
National Center for Advancing Translational Sciences · UL1
PI · $12.4M · Albert Einstein College of Medicine, Inc
Clinical trials
- 2017
Principal investigator · Terminated · Phase 1
Marla Keller
- 2013–2014
Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring
Principal investigator · Completed · Phase 1
Albert Einstein College of Medicine
- 2009
Safety of Acidform Lubricant in HIV-Uninfected Women
Principal investigator · Completed · Phase 1
National Institute of Allergy and Infectious Diseases (NIAID)
- 2010
Principal investigator · Completed · Phase 1
National Institute of Allergy and Infectious Diseases (NIAID)




